

Review

Not peer-reviewed version

Current Management and Treatment Paradigms of Gastroesophageal Reflux Disease Following Sleeve Gastrectomy

Muaaz Masood , Donald E Low , Shanley B. Deal , [Richard A. Kozarek](#) *

Posted Date: 19 January 2024

doi: 10.20944/preprints202401.1493.v1

Keywords: Gastroesophageal, reflux; GERD, esophagitis, morbid, obesity, bariatric, gastric, sleeve, gastrectomy



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article

Current Management and Treatment Paradigms of Gastroesophageal Reflux Disease Following Sleeve Gastrectomy

Muaaz Masood ¹, Donald Low ², Shanley B. Deal ³ and Richard A. Kozarek ^{1,4,*}

¹ Division of Gastroenterology and Hepatology, Center for Digestive Health, Virginia Mason Franciscan Health, Seattle, Washington, USA

² Division of Thoracic Surgery, Center for Digestive Health, Virginia Mason Franciscan Health, Seattle, Washington, USA

³ Division of General and Bariatric Surgery, Center for Weight Management, Virginia Mason Franciscan Health, Seattle, Washington, USA

⁴ Center for Interventional Immunology, Benaroya Research Institute, Virginia Mason Franciscan Health, Seattle, Washington, USA

* Correspondence: address all correspondence to: Richard A. Kozarek, MD, Center for Digestive Health, Virginia Mason Franciscan Health Center for Interventional Immunology, Benaroya Research Institute 1201 Ninth Ave Seattle, Washington 98101, USA Tel: 206.515.5397 Email: richard.kozarek@virginiamason.org Article Guarantor: Richard A. Kozarek, MD

Abstract: Obesity is associated with serious comorbidities and economic implications. Bariatric surgery, most commonly Roux-en-Y gastric bypass and sleeve gastrectomy, are effective options for weight loss and improvement of obesity-related comorbidities. With the growing obesity epidemic, there has been a concomitant rise in bariatric surgeries, particularly in sleeve gastrectomy, which has been the most widely performed bariatric surgery since 2013. Gastroesophageal reflux disease (GERD) is highly prevalent in obese individuals, can significantly impact quality of life and may lead to serious complications. Obesity and GERD both improve with weight loss. However, as the incidence of sleeve gastrectomy rises, recent data has revealed a risk of exacerbation of pre-existing GERD or the development of de novo GERD following sleeve gastrectomy. We performed a detailed review of GERD post-sleeve gastrectomy, including its overall incidence, pathophysiology and current treatment paradigms.

Keywords: gastroesophageal; reflux; GERD; esophagitis; morbid; obesity; bariatric; gastric; sleeve; gastrectomy

Short title: GERD Following Sleeve Gastrectomy

1. Introduction

Obesity, defined as a body-mass index (BMI) >30 kg/m², affects approximately 4 out of 10 individuals in the United States and has serious health and economic implications [1]. The World Obesity Foundation has projected that over 4 billion people, or half of the world's current population, will be overweight or obese by 2035 (World Obesity Federation, World Obesity Atlas, 2023). Coinciding with the growing obesity epidemic, there has been an increase in the rate of bariatric surgeries over the last two decades [2]. Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) are the most commonly performed bariatric surgeries [2]. Sleeve gastrectomy surpassed RYGB in 2013 and continues to be the most widely performed bariatric surgery to date [2,3]. A shift towards minimally invasive bariatric surgery compared to open bariatric surgery has also been evident over the past 20 years [2].

Gastroesophageal reflux disease (GERD) is a chronic condition which is highly prevalent in obese individuals [4,5]. GERD manifests as heartburn and regurgitation though atypical or extraesophageal symptoms, in particular cough and chest pain, may be present in up to one-third of

patients [6]. GERD has been documented in 62.4%-73% of candidates for bariatric surgery [7,8]. Obesity and GERD both improve with weight loss [9,10]. However, as the incidence of minimally invasive SG increases, emerging data has revealed a risk of worsening GERD post-SG [3,11–15]. De novo GERD has also been reported after SG [11,12,16–18]. We performed a detailed review of GERD following SG, including its overall incidence, pathophysiology and current treatment paradigms.

2. Methods

We conducted a narrative review of the literature pertaining to GERD following sleeve gastrectomy using PubMed and Google Scholar computerized search to identify articles with the title or keywords “GERD”, “gastroesophageal”, “reflux”, “obesity”, “bariatric surgery”, “laparoscopic”, “sleeve gastrectomy” and “gastric sleeve”. Systematic reviews, meta-analyses, randomized controlled trials and clinical trials were prioritized. Articles that were unrelated to the topic and duplicate articles were removed. Articles that were not available in English or full text were excluded. Articles regarding reflux in the context of pregnancy were excluded. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. A total of 103 articles were included in the final review. The articles were independently reviewed by two authors. The authors provided representative, anonymized radiographic and endoscopic images to highlight the issues outlined in the manuscript.

3. Discussion

3.1. *What is the evidence for worsening GERD following SG?*

As the incidence of SG rises, GERD following SG has become a notable concern. A multitude of studies have associated sleeve gastrectomy with the exacerbation of pre-existing GERD (Table 1). In a study of 66 patients, the prevalence of GERD symptoms (12.1% vs. 47 %) and erosive esophagitis (16.7 vs. 66.7 %) was significantly increased following LSG [12]. In addition, erosive esophagitis was correlated with the presence of a hiatal hernia following LSG in the study [12]. A retrospective review of 28 patients suggested that LSG may increase in the prevalence of GERD despite adequate weight loss [13]. Matar et al. retrospectively reviewed 517 patients and noted a higher prevalence of EE (37.9% vs. 17.6%, $p = 0.0001$), including severe EE, with SG vs. RYGB [14]. A decreased resting lower esophageal sphincter was also noted in the SG group [14]. A prospective, nonrandomized, open-label study of 30 patients noted GERD in two-thirds of patients following LSG [19]. A meta-analysis by Gu et al. exploring the correlation between bariatric surgery (LSG and RYGB) and GERD revealed that risk of GERD was five times greater with LSG compared to LRYGB (pooled OR of 5.10, $p < 0.001$) [15]. LRYGB was demonstrated to be more effective for the treatment of GERD in obese patients in the study [15]. DuPree et al. revealed that only 15.9% of 4832 patients demonstrated GERD resolution after SG whereas the vast majority of patients continued to have GERD symptoms [16]. Preoperative GERD was associated with significantly increased postoperative complications, gastrointestinal adverse events and need for revisional surgery in the study [16]. Increased PPI usage has also been reported following LSG compared to LRYGB 1-2 years postoperatively [11]. A retrospective study involving 176 patients revealed that 34.6% of patients had preoperative GERD complaints, 49% had GERD symptoms within 30 days following LSG and 47.2% had GERD symptoms for greater than one month after LSG [17]. The recent multicenter, randomized controlled study of 240 patients comparing outcomes in gastric sleeve vs. gastric bypass, termed the SLEEVEPASS trial, reported a significantly higher PPI intake (64% vs. 36%, $p < 0.001$), higher GERD-HRQL total score (10.5 vs. 0, $p < 0.001$), more reflux symptoms and higher prevalence of esophagitis (31% vs. 7%, $p < 0.01$) in the LSG group [20]. The SM-BOSS trial of 217 patients noted that 31.8% developed worsening GERD at 5 years based on patients' symptoms and medication usage. Moreover, a study by Raj et al. noted that up to 35% of patients may experience GERD following laparoscopic SG (LSG) [19].

Table 1. Comparison of de-novo and pre-existing gastroesophageal reflux disease / erosive esophagitis and acid suppression medication use in the setting of sleeve gastrectomy. Abbreviations: BE = Barrett's esophagus, EE = erosive esophagitis, GERD = gastroesophageal reflux disease, NR = not reported, OR = odds ratio, PPI = proton-pump inhibitor, RYGB = Roux-en-Y gastric bypass, SG = sleeve gastrectomy.

First Author	Year Published	Article Type	Number of Cases or Studies	Rate of de novo or new-onset GERD	Comparison of GERD or erosive esophagitis in the setting of SG	Comparison of acid suppression medication use in the setting of SG	Additional comments
Tai [12]	2013	Retrospective review	66 cases	44.8%	GERD: 12.1% (pre-SG) → 47% (post-SG)	NR	Increase in hiatal hernias (6.1% → 27.3%) following SG
Gu [15]	2019	Systematic review and meta-analysis	23 studies	NR	GERD post-SG vs. post-RYGB, OR = 5.10, $p < 0.001$	NR	
Howard [13]	2011	Retrospective review	28 cases	18%	NR	NR	
Matar [14]	2020	Retrospective review	517 cases	NR	Prevalence of EE higher post-SG (37.9%) vs. post-RYGB (17.6%), $p = 0.0001$	NR	
Carter [17]	2011	Retrospective review	176 cases		34.6% (pre-SG) → 49% (post-SG at 30 days) → 47.2% (post-SG >30 days)	22% (pre-SG) → 33.8% (post-SG), $p = 0.0428$	
DuPree [16]	2014	Retrospective review	4832 cases	8.6%	GERD pre-SG: 44.5% 84.1% of post-SG cases with continued GERD	NR	
Sheppard [11]	2015	Retrospective review	387 cases	NR	NR	28% pre-SG PPI use Only 2% of cases were able to discontinue PPI post-SG	
Joudeikis [21]	2017	Systematic review and meta-analysis	20 studies	NR	GERD improved in 30.6% of patients	NR	
Mion [22]	2016	Retrospective review	53 cases	NR	Frequent, impedance reflux episodes (52%) post-SG associated with GERD symptoms and	NR	

					esophageal dysmotility		
Peterli [23]	2018	Randomized controlled trial	217 cases	31.6%	31.8% had worsening of symptoms or increase in therapy at 5 years post-SG		
Genco [24]	2017	Prospective review	110 cases	NR	33.6% (pre-SG) → 68.1% (post-SG), p <0.001	PPI use: 19.1% (pre-SG) → 57.2% (post-SG), p < 0.001	Non- dysplastic BE was newly diagnosed in 17.2% of cases
Han [25]	2020	Systematic review and meta-analysis	20 studies	Pooled RR of de novo GERD with SG vs. RYGB was 0.33 (95% CI: 0.15 to 0.68, P = 0.003)	Pooled RR of NR GERD symptoms with SG vs. RYGB was 0.16 (95% CI: 0.06 to 0.44; P = 0.0004)		
Oor [26]	2016	Systematic review and meta-analysis	33 studies	20%	New-onset esophagitis: 6.3%-63.3%	NR	High heterogeneity among studies
Salminen [20]	2022	Randomized clinical trial	228 cases	NR	49% of cases reported worsening GERD post- SG at 10 years	PPI use: 64% at 10 years post-SG	De novo BE: 4%
					31% had esophagitis at 10 years post- SG		
Yeung [27]	2020	Systematic review and meta-analysis	46 studies	23%	23% increase in GERD post-SG	NR	Long-term prevalence of esophagitis was 28% and of BE was 8%
Znamirowski [28]	2023	Systematic review and meta-analysis	9 studies	50.8%	GERD: 26% (pre-SG) → 61.6% (post- SG)	NR	Significant heterogeneity among studies was reported
							BE was reported in 7.3% of cases across all studies

3.2. Is de novo GERD a topic of concern following sleeve gastrectomy?

In addition to worsening of pre-existing GERD, new-onset or de novo GERD has been widely reported after SG as detailed in Table 1. In a recent meta-analysis by Znamirowski et al., the pooled odds ratio (OR) for overall GERD occurrence post-LSG across 8 studies was 3.61 (p < 0.001) [28]. The combined percentage of patients with de novo GERD across 5 studies was 50.8% [28]. Across 7 studies, the combined percentages of patients with LA Grade C and LA Grade D esophagitis were

4.3% and 3.3% respectively [28]. However, significant heterogeneity was noted in the study [28]. In addition, there was variability in how GERD was documented as studies used patients' symptoms, PPI usage, endoscopic findings, pH testing, esophageal manometry or a combination of these parameters. A meta-analysis by Han et al. reported that the pooled risk ratio of de novo GERD for SG vs. RYGB was 0.33 (95% confidence interval: 0.15 – 0.68; $p = 0.003$) [25]. Additional meta-analyses by Yeung and Oor have reported rates of de novo GERD to be 20% and 23% respectively [26,27]. Finally, the SM-BOSS trial noted that 31.6% of 217 patients developed de novo GERD at 5 years based on patients' symptoms and medication usage [23].

Overall, these data highlight that there is a persistent concern for worsening and de novo GERD after SG. The risk of exacerbation of pre-existing GERD and the development of new-onset GERD should be considered when assessing patients for SG.

3.3. What are the underlying mechanisms for de novo or increased GERD following a sleeve gastrectomy?

There are factors which may contribute to alleviating GERD after SG including weight loss leading to decreased abdominal pressure, reduced gastric volume and possibly accelerated gastric emptying [29,30]. In contrast, several pathophysiological mechanisms for de novo or increased GERD following SG have been described. Anatomic disruption of the antireflux barrier, including the esophagogastric junction, gastroesophageal flap valve, the angle of His, the gastric sling fibers and the fundus, may result in an increasing propensity for the reflux of gastric contents. Others discuss that caution must be made when positioning the staple line during SG in a manner that will preserve the antireflux barrier [31]. In contrast to RYGB, SG may be more likely to disrupt the angle of His and gastroesophageal junction attachments. There may be a functional impairment at the gastroesophageal junction such as with a hiatal hernia (Figures 1 and 2). In one study, 37% of 181 morbidly obese patients were noted to have a hiatal hernia during preoperative work-up for bariatric surgery [32]. Repair of hiatal hernia, if present, at the time of SG is recommended to reduce the risk of post-operative GERD though hiatal hernia repair may pose a challenge in patients with large hernias especially those associated with esophagitis or Barrett's esophagus [32,33].




Figure 1. Upper gastrointestinal series in a patient post-sleeve gastrectomy with early satiety and reflux reveals the following: a small, hiatal hernia and gastroesophageal reflux (blue arrow, left) in addition to abnormal angulation (blue arrow, right) and dilation of the gastric sleeve (green arrow, right). The patient underwent conversion to Roux-en-Y gastric bypass with marked clinical improvement.




Figure 2. An upper gastrointestinal series reveals a moderate, sliding type one hiatal hernia (bottom arrow) in addition to gastroesophageal reflux disease (top arrow) in a patient with morbid obesity.

Conditions in which there is an increase in intragastric pressure may lead to reflux. Greenan et al. explored gastric pressurization using high resolution manometry and reflux using pH impedance in patients post-SG, post-RYGB as well as in symptomatic and asymptomatic control groups. Patients in the SG group had higher acid exposure time (median 6.0% vs. 0.2%), reflux episode numbers (median 63.0 vs. 37.5) and baseline intragastric pressure (median 17.3 mmHg vs. 13.1 mmHg) compared to the RYGB group, $p < 0.001$ [34].

Complications of SG, including stenosis, angulation or kinking, are associated with increased intragastric pressure and GERD (Figure 1) [35]. Data regarding the optimal bougie size for weight loss and reduced reflux are mixed, but generally support a range of 36–42 French [36–40]. Overfilling of the gastric sleeve due to a large meal portion may result in reflux symptoms and thus, patients should be counseled to gradually advance their diet from liquids to small portions of healthy, protein-rich foods. The gastric sleeve dimensions should be sufficient as too narrow of a gastric sleeve may result in increased intragastric pressure and subsequent reflux. An abnormally narrow sleeve may also lead to regurgitation due to overfilling even in patients with a competent lower esophageal sphincter and no hiatal hernia. Felinska et al. described the ideal shape of a gastric sleeve to be a trapezoid with a wide antrum and a narrow cardia to prevent sleeve stenosis or increased pressure within the stomach [31]. Furthermore, preservation of the antrum has been suggested to increase gastric emptying and reduce subsequent GERD [41]. Esophagogastric dysmotility may be a

contributing factor to post-SG GERD and a dynamic contrast study can be a useful test in establishing the diagnosis.

3.4. What are the current management and treatment paradigms of GERD following SG?

3.4.1. Lifestyle modifications

A comprehensive, stepwise approach to the management and treatment of GERD following SG has recently been published by Masood et al. [42]. Lifestyle modifications are initially recommended following SG as part of a comprehensive bariatric surgery center's pre- and post-operative education and long-term follow-up plan with patients. Dietary education should emphasize gradual progression of the postoperative diet from liquids to eventually healthy, protein-rich meals. Small portion sizes, typically $\frac{1}{2}$ to 1 cup or 4 to 6 ounces, are suggested. Overfilling the stomach with a large portion may exacerbate reflux and induce regurgitation or food stasis in the distal esophagus, which may also be interpreted as GERD-like symptoms, or induce stasis esophagitis if overfilling occurs repeatedly (Figure 3). Counseling regarding exercise, nutritional supplementation, treatment of constipation and avoidance of underlying risk factors of GERD i.e. alcohol, tobacco, caffeine, chocolate and postprandial supination, should be provided.



Figure 3. An upper gastrointestinal series reveals contrast filling of sleeve with reflux of a column of contrast into the distal esophagus (blue arrow) in a patient following sleeve gastrectomy.

3.4.2. Optimization of medication regimens

Patients are often prescribed a PPI or histamine-2 receptor antagonist (H2RA) to prevent ulcer formation and reflux. In patients with post-SG GERD, PPI and H2RA regimens should be reviewed and optimized accordingly. Of note, the novel potassium-competitive acid blocker, vonoprazan, has shown promising results in PPI-refractory GERD though its use has not been assessed in the bariatric surgery population [43–45].

3.4.3. Diagnostic work-up

The authors recommend obtaining an esophagram, EGD, manometry and pH testing in selected patients presenting with GERD following SG for further anatomic and physiologic evaluation of symptoms. Post-SG complications should be promptly identified and corrected. Stenosis, angulation and kinking of the gastric sleeve are associated with increased intragastric pressure and reflux (Figure 3) [35]. Ulcers and gastric sleeve leaks should be addressed appropriately.

3.4.4. Treatment of underlying postoperative complications: gastric sleeve stenosis

Endoscopic balloon dilation (EBD) has been shown to be a safe and efficacious modality for gastric sleeve stenosis (GSS) (Figure 4) [46,47]. A meta-analysis by Chang et al. of 18 studies involving a total of 426 patients revealed an overall success rate of 76% and an average of 1.8 dilations per patient [48]. Proximal GSS had a higher efficacy rate of 90% compared to distal GSS which had an efficacy rate of 70% [48]. Studies in the meta-analysis utilized through-the-scope controlled radial expansion balloons, pneumatic balloons used for achalasia or a combination of the two [48]. The optimal balloon type, balloon size and the number of dilations required remains unclear [49]. Fully covered self-expanding metal stents (FCSEMS) have been reported to be effective in 70% of cases in which EBD failed though stent migration remains a concern [48,50].




Figure 4. (Left) An upper gastrointestinal series in a patient status post-sleeve gastrectomy with recurrent dysphagia reveals dilation of the gastric sleeve at the cardia (blue arrow) with narrowing and delayed passage of contrast through the middle and distal portions (green arrows) of the gastric sleeve. (Middle) The patient underwent serial endoscopic through-the-scope balloon dilation to 20 mm (blue arrow) with improvement in sleeve stenosis (right) and dysphagia.

3.4.5. Treatment of underlying postoperative complications: gastric sleeve leak

It is noteworthy to mention gastric sleeve leak (GSL), a serious, life-threatening complication of SG, which involves the leak of gastrointestinal contents from the staple line into the abdominal cavity. GSL may occur at any point along the staple line from the gastroesophageal junction to the antrum though they most commonly occur at the angle of His. GSL confers a high risk of morbidity and mortality. The leak rate has been reported to be between 1% to 5% for patients who undergo SG as a primary procedure. The leak rate is >10% for patients who underwent SG as a revisional procedure, after failed laparoscopic adjustable gastric banding or vertical banded gastroplasty, likely due to increased dissection, prior staple lines, vascular integrity and overall quality of tissues adhesions which may be encountered during a reoperation [51–54].

Csendes and Burgos proposed a classification of GSL according to timing, location and severity of the leak [52,55]. Type I (subclinical) leaks are well-defined without septic complications or dissemination into the abdominal or pleural cavity. Type II leaks (clinical) are outlined by septic complications with generalized dissemination into the abdominal or pleural cavity. Leaks may be classified based on timing as early, intermediate and late if they occur 1-3 days, 4-7 days and ≥ 8 days

following surgery, respectively. Leaks may also be classified using a combination of clinical and radiologic data as follows: Type A are microperforations without clinical or radiologic evidence of leak, Type B are leaks noted on radiographic studies without a clinical finding and Type C are leaks with both radiologic and clinical evidence [56]. GSL may manifest as sepsis, abdominal pain, chest/shoulder pain, dizziness or it can be asymptomatic. Radiographic imaging, including upper gastrointestinal series and CT with contrast, are typically helpful in establishing the diagnosis.

Management of GSL may include initial measures (i.e. broad spectrum IV antibiotics, IV fluids, NPO status, distal enteral tube feeding), surgical consultation, early oversewing and open or laparoscopic drainage [54]. In recent years, several endoscopic techniques have been utilized in the management of GSL including covered SEMS (partially covered or fully covered), internal drainage using transgastric double pigtail stents, over-the-scope clips, endoscopic suturing and the use of sealants i.e. fibrin glue or cyanoacrylate [57].

A novel endoscopic modality known as endoscopic vacuum therapy (EVT) involves the placement of a wound vac sponge near the leak site. The sponge is attached to a nasogastric tube and continuous suction is applied using a wound vac device which aids in the removal of fluid, pus and necrotic debris from the site [58]. The sponge is typically replaced endoscopically every 3 to 7 days. Additionally, patients often require a percutaneous endoscopic jejunostomy tube for enteral nutrition while the sponge is in place. Several studies report that EVT is safe and effective [59–61]. Although its feasibility as an initial modality for the treatment of sleeve leak is limited given that it typically requires multiple endoscopic procedures, there may be a role for EVT in refractory cases of sleeve leak [57]. Ultimately, some patients who have failed prior therapies for sleeve leaks undergo conversion to RYGB or total gastrectomy [54].

3.4.6. Discussion of risks related to GERD with potential candidates for sleeve gastrectomy

Due to the association of SG with an increased risk of GERD, it is paramount for clinicians to discuss the risk of exacerbation of pre-existing GERD and the development of new-onset GERD during the shared decision-making process with potential candidates for SG (Figure 5). Data regarding the long-term risk of PPI use and the risk of cardiovascular adverse events should be considered as it relates to the treatment of GERD post-SG.




Figure 5. Upper endoscopy demonstrates Los Angeles Grade C esophagitis in a patient following sleeve gastrectomy (arrows, left). A Bravo™ capsule was placed endoscopically for pH monitoring (Medtronic, Minneapolis, Minnesota, USA) (arrow, right).

An international expert panel on sleeve gastrectomy reported that 52.5% of general surgeons and 23.3% of bariatric surgeons considered GERD as a contraindication to SG [62]. According to a multi-society consensus statement, SG should not be performed as an anti-reflux procedure [63]. Data suggests that patients with a BMI >35 and medically refractory GERD should be considered for RYGB rather than fundoplication due to the following: an increased risk of hiatal hernia and GERD recurrence with fundoplication in patients with BMI >35 as well as an additional weight loss and metabolic benefit conferred by RYGB to address a myriad of comorbidities [63–67].

3.4.7. Conversion to Roux-en-Y gastric bypass

Conversion from SG to RYGB is ultimately necessary for some patients with refractory GERD post-SG (Figure 6). There is robust data that conversion to RYGB is very effective for the treatment of GERD, as detailed in Table 2, in addition to its beneficial effects on weight loss and other comorbidities (i.e. diabetes, hypertension, dyslipidemia). In a recent retrospective study by MacVicar et al., 4412 patients required revisional surgery due to GERD which comprises 24% of all conversion procedures [68]. SG was the original surgery in 80.1% of cases and Roux-en-Y was the revisional surgery in 84.4% of cases [68].




Figure 6. Endoscopic images reveal a 3-cm hiatal hernia (arrows, top left) and Los Angeles Grade B esophagitis (arrows, top right) in the lower-third of the esophagus with narrow-band imaging in a patient post-sleeve gastrectomy with symptoms of gastroesophageal reflux disease. The patient eventually required Roux-en-Y gastric bypass (arrow, bottom) and concomitant hiatal hernia repair as demonstrated on upper gastrointestinal series.

Many studies reveal significant improvement in GERD symptoms and the use of acid suppression medications following conversion to RYGB. Studies by Langer et al. and Gautier et al. both reported that all patients were able to discontinue acid suppressive medications [69,70]. Parmar et al. revealed that 80% of patients discontinued acid suppressive medications whereas Hendricks et al. documented that 75% of patients had complete resolution of GERD with conversion to RYGB [71,72]. A study by Strauss et al. concluded that 80.2% of patients who underwent conversion to RYGB had improvement in GERD symptoms [73].

The average rate of conversion from SG to RYGB due to GERD has been approximately 5-10% [23,27,74]. In the SLEEVEPASS trial, the rate of conversion to RYGB was noted to be 6% [74]. In the SM-BOSS trial, the reported rate of conversion to RYGB was 9% [23]. In a meta-analysis of 46 studies by Yeung et al., 4% of patients underwent conversion to RYGB [27]. However, some studies report a higher rate of conversion [69,71,73,75]. In addition, Han et al. revealed that RYGB may be superior to SG with regard to GERD improvement with a pooled risk ratio of 1.48 (95% confidence interval: 1.07 – 2.04; $P = 0.02$) [25]. Of note, in a retrospective study by Dang et al., conversion from SG to RYGB compared to primary RYGB was associated with an increased rate of serious complications (7.2% vs. 5%, $p < 0.001$) including anastomotic leaks, bleeding and reoperation [76]. There was no significant difference in mortality between SG to RYGB compared to primary RYGB in the study [76].

Table 2. Comparison of studies exploring the effect of conversion from sleeve gastrectomy to Roux-en-Y gastric bypass as it relates to gastroesophageal reflux disease. Abbreviations: ASM = acid suppression medications, BE = Barrett's esophagus, EE = erosive esophagitis, GERD = gastroesophageal reflux disease, NR = not reported, OR = odds ratio, PPI = proton-pump inhibitor, RYGB = Roux-en-Y gastric bypass, SG = sleeve gastrectomy.

First Author	Year Published	Article Type	Number of Cases or Studies	Conversion rate to RYGB for GERD	Effect on GERD and use of acid suppression medications
Yeung [27]	2020	Systematic review and meta-analysis	46 studies	4%	NR
Salminen [74]	2018	Randomized controlled trial	240 cases	6%	NR
Peterli [23]	2018	Randomized controlled trial	217 cases	9%	NR
Langer [69]	2010	Retrospective review	73 cases	11%	100% with severe reflux discontinued ASM
Parmar [71]	2017	Prospective study	22 cases	45.5%	100% reported improvement in GERD symptoms
Abdemur [77]	2016	Retrospective review	1118 cases	0.8%	80% were able to discontinue ASM 66% had complete resolution of GERD symptoms
Hendricks [72]	2016	Retrospective review, comparative study	919 cases	10.5%	75% of patients had complete resolution of GERD symptoms 25% of patients had partial resolution of GERD symptoms
Gautier [70]	2013	Retrospective review	481 cases	1.24%	100% of patients discontinued ASM
Strauss [73]	2023	Retrospective review	97 cases	72.2%	No recurrence of GERD was noted 80.2% of patients had improvement in GERD symptoms
Felsenreich [75]	2022	Retrospective review	79 cases	34.2%	19.4% of patients were able to discontinue ASM 29.9% of patients reported GERD symptoms following conversion
Peng [78]	2020	Systematic review and meta-analysis	40 studies	NR	57.1–100% had remission or improvement in GERD symptoms

3.4.8. Sleeve gastrectomy with fundoplication or hiatal hernia repair

Due to the prevalence of hiatal hernias in the bariatric population, several studies have explored GERD outcomes when SG is combined with either fundoplication or hiatal hernia repair (Figures 7 and 8) [79–91]. The authors acknowledge that the published studies on SG combined with either fundoplication or hiatal hernia repair are investigational with a limited sample size and variable follow-up. We summarize the published data regarding SG combined with either fundoplication or

hiatal hernia repair to highlight experimental approaches to GERD post-SG beyond conversion to RYGB with hiatal hernia repair.




Figure 7. An upper gastrointestinal series reveals a small, sliding hiatal hernia (bottom arrow) in addition to gastroesophageal reflux disease (top arrow) in a patient following sleeve gastrectomy.



Figure 8. An upper gastrointestinal series reveals a small, sliding hiatal hernia (bottom arrow) with spontaneous gastroesophageal reflux (top arrow) in a patient following sleeve gastrectomy.

A randomized clinical trial comparing SG with SG and Rosetti fundoplication (RF) by Olmi et al. concluded that there was a significant reduction in PPI use and esophagitis in the SG with RF group compared to the SG group [85]. Wrap perforation occurred in 4.3% of patients and reportedly improved with the surgeon's learning curve [85]. In a study of 220 patients who underwent SG with modified RF and a follow-up period of 24 months, 98.5% of cases did not report GERD or use PPIs and 97% of cases had endoscopic improvement in esophagitis [86]. A prospective study of 25 patients who underwent laparoscopic Nissen-SG (N-Sleeve) concluded that 76% of patients remained asymptomatic without requiring PPI at 3 months [92]. Twelve percent of patients reported reflux at 6 months and 12 months postoperatively [92]. In a study of 32 patients with GERD/esophagitis who underwent SG with anterior fundoplication (D-Sleeve), comparison of high-resolution impedance manometry and multichannel intraluminal impedance before and after the D-sleeve surgery revealed improved lower esophageal sphincter function and notable control of esophageal acid exposure and reflux events at 14 months [89].

A systematic review and meta-analysis by Castagneto-Gissey et al. compared the efficacy of SG with fundoplication vs. SG with hiatal hernia repair as it relates to GERD remission across 15 studies with a total of 1164 patients [79]. The mean follow-up was 37.3 ± 28.1 months after SG with hiatal hernia repair and 17.4 ± 9.3 months after SG with fundoplication [79]. Most studies defined GERD based on patients' symptoms, with severity evaluated using scales or scores, and the use of antacids or PPIs [79]. Five studies in the meta-analysis utilized objective assessment including endoscopy,

manometry or upper gastrointestinal contrast studies to diagnose GERD [79]. Both SG with hiatal hernia repair and SG with fundoplication were effective in GERD resolution and weight loss outcomes [79]. However, SG with RF resulted in significantly greater GERD remission compared to SG with hiatal hernia repair though a higher complication rate was noted in the SG with RF group [79]. SG with fundoplication has been described to be relatively safe with a postoperative complication rate of 9.4% in a review by Carandina et al [80]. While there are preliminary data regarding SG with fundoplication, the authors conclude that additional, high-quality studies are warranted to determine the long-term safety and efficacy of SG with fundoplication.

3.4.9. The use of magnetic sphincter augmentation devices

Magnetic sphincter augmentation (MSA) devices, such as the LINX® system, have also been used as an experimental approach to mitigate post-SG GERD. MSA devices utilize titanium beads with a magnetic core connected with titanium wires to form a ring shape which is laparoscopically placed around the lower esophageal sphincter as a reinforcement (Figures 9 and 10). Some studies have revealed favorable results [93–97]. A meta-analysis of 3 studies with a total of 33 patients revealed a pooled mean difference between preoperative and postoperative GERD-Heath-Related Quality of Life Questionnaire (GERD-HRQL) scores to be 17.5 following MSA [98]. However, data are limited. Further studies are warranted to establish the safety and efficacy of MSA devices following SG.




Figure 9. Laparoscopic image reveals a patient status post-sleeve gastrectomy with a defect in the diaphragmatic hiatus (arrow) and subsequent gastroesophageal reflux disease. Image courtesy of Dr. Brian Louie, Chief of Thoracic Surgery at Swedish Medical Center in Seattle, Washington, USA.




Figure 10. Laparoscopic image demonstrates hiatal hernia repair and successful placement of a magnetic sphincter augmentation device (arrow) around the esophagus in a patient status post-sleeve

gastrectomy with gastroesophageal reflux disease. Image courtesy of Dr. Brian Louie, Chief of Thoracic Surgery at Swedish Medical Center in Seattle, Washington, USA.

3.4.10. Endoscopic sleeve gastropasty

Of note, a recent technique known as endoscopic sleeve gastropasty (ESG), or endoluminal vertical gastropasty (EVG), has been reported to be a safe and effective primary weight loss procedure or revisional procedure for weight recidivism in the setting of SG and has also shown promising results with regard to GERD improvement [99–102]. According to a case-matched study by Fayad et al., new-onset GERD was significantly lower in the ESG group compared with the LSG group (1.9% vs 14.5%, $P < .05$) which may be due to sparing of both the fundus of the stomach and attachments to the gastroesophageal junction [103]. In a multicenter study of 18 patients, the Transoral Gastric Volume Reduction as Intervention for Weight Management (TRIM) trial, which evaluated outcomes in transoral gastric volume reduction surgery using an endoscopic suturing system, reported a reduction in patients who reported reflux from 8 of 14 patients prior to the procedure to 5 out of 14 at 1-year follow-up [104]. Further studies are needed to determine the effect of ESG on GERD.

3.4.11. Surveillance for Barrett's esophagus post-sleeve gastrectomy

It is important to note that emerging data has revealed an association of Barrett's esophagus (BE) following SG. According to 2 recent meta-analyses by Yeung and Qumseya, the prevalence of BE following SG is approximately 8% and 11.6%, respectively [27,105]. While the current data regarding BE following SG has limitations, it suggests that endoscopic surveillance is important following SG. The American Society for Metabolic and Bariatric Surgery (ASMBS) has recommended to offer screening for BE in SG patients 3 or more years post-SG, regardless of the presence of GERD symptoms, in addition to the standard screening indications for GERD and Barrett's esophagus [106].

4. Conclusion

With the growing obesity epidemic and concomitant rise in bariatric surgery, particularly sleeve gastrectomy, there is robust data that sleeve gastrectomy is associated with an exacerbation of pre-existing GERD and the development of de novo GERD due to several pathophysiological mechanisms. Current management and treatment paradigms should include the following: lifestyle modifications, optimization of PPI and H2RA regimens, diagnostic work-up (i.e. esophagram, EGD, manometry and pH testing) as indicated in select patients and prompt endoscopic or surgical treatment of postoperative complications (i.e. gastric sleeve stenosis, angulation, kinking, leaks). Conversion to RYGB currently has the most robust data for its safety and efficacy for the treatment of medically refractory GERD post-SG. Discussion and shared decision making regarding the risk of worsening or new-onset GERD with potential candidates for sleeve gastrectomy is paramount. Data suggest that patients with a BMI >35 and medically refractory GERD should be considered for RYGB rather than fundoplication. Due to the reports of Barrett's esophagus following sleeve gastrectomy, the ASMBS recommends that endoscopic surveillance should be offered to patients 3 or more years following sleeve gastrectomy, regardless of the presence of GERD symptoms, in addition to standard screening indications for GERD and Barrett's esophagus. Further studies are warranted to determine the role of sleeve gastrectomy combined with fundoplication or hiatal hernia repair, endoscopic sleeve gastropasty and the use of magnetic sphincter augmentation devices in relation to GERD.

Author Contributions: Conceptualization, M.M., R.A.K., D.L. and S.B.D.; methodology, M.M., R.A.K., D.L. and S.B.D.; software, not applicable; validation, M.M., R.A.K., D.L. and S.B.D.; formal analysis, M.M., R.A.K., D.L. and S.B.D.; investigation, M.M., R.A.K., D.L. and S.B.D.; resources, M.M., R.A.K., D.L. and S.B.D.; data curation, M.M., R.A.K., D.L. and S.B.D.; writing—original draft preparation, M.M.; writing—review and editing, M.M., R.A.K., D.L. and S.B.D.; visualization, M.M., R.A.K., D.L. and S.B.D.; supervision, R.A.K., D.L. and S.B.D.; project administration, M.M. and R.A.K.; funding acquisition, not applicable. All authors have read and agreed to the published version of the manuscript.

Funding: All authors have no financial disclosure or support to report. There were no external sources of funding for this manuscript.

Institutional Review Board Statement: not applicable.

Data Availability Statement: not applicable. This manuscript has not been previously published and is not currently under consideration elsewhere for publication.

Acknowledgments: The authors would like to thank Dr. Brian Louie, Chief of Thoracic Surgery at Swedish Medical Center in Seattle, Washington, USA, for his assistance in providing the laparoscopic images pertaining to the magnetic sphincter augmentation device. The authors would also like to thank Terri Davis Smith from the Center for Digestive Health at Virginia Mason Franciscan Health in Seattle, Washington, USA, for her assistance in the coordination and the submission of the manuscript.

Conflicts of Interest: No conflict of interest exists for all authors in this manuscript.

References

1. Stierman B, Afful J, Carroll MD, Chen T-C, Davy O, Fink S, et al. National health and nutrition examination survey 2017–March 2020 prepandemic data files development of files and prevalence estimates for selected health outcomes. 2021.
2. Alalwan AA, Friedman J, Park H, Segal R, Brumback BA, Hartzema AG. US national trends in bariatric surgery: A decade of study. *Surgery*. 2021;170(1):13-7.
3. Clapp B, Ponce J, DeMaria E, Ghanem O, Hutter M, Kothari S, et al. American Society for Metabolic and Bariatric Surgery 2020 estimate of metabolic and bariatric procedures performed in the United States. *Surg Obes Relat Dis*. 2022;18(9):1134-40.
4. Delshad SD, Almario CV, Chey WD, Spiegel BMR. Prevalence of Gastroesophageal Reflux Disease and Proton Pump Inhibitor-Refractory Symptoms. *Gastroenterology*. 2020;158(5):1250-61.e2.
5. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. *Gut*. 2014;63(6):871-80.
6. Durazzo M, Lupi G, Cicerchia F, Ferro A, Barutta F, Beccuti G, et al. Extra-Esophageal Presentation of Gastroesophageal Reflux Disease: 2020 Update. *J Clin Med*. 2020;9(8).
7. Sharara AI, Rustom LBO, Bou Daher H, Rimmani HH, Shayto RH, Minhem M, et al. Prevalence of gastroesophageal reflux and risk factors for erosive esophagitis in obese patients considered for bariatric surgery. *Dig Liver Dis*. 2019;51(10):1375-9.
8. Merrouche M, Sabaté JM, Jouet P, Harnois F, Scaringi S, Coffin B, Msika S. Gastro-esophageal reflux and esophageal motility disorders in morbidly obese patients before and after bariatric surgery. *Obes Surg*. 2007;17(7):894-900.
9. El-Serag HB, Graham DY, Satia JA, Rabeneck L. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. *Am J Gastroenterol*. 2005;100(6):1243-50.
10. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. *Ann Intern Med*. 2005;143(3):199-211.
11. Sheppard CE, Sadowski DC, de Gara CJ, Karmali S, Birch DW. Rates of reflux before and after laparoscopic sleeve gastrectomy for severe obesity. *Obes Surg*. 2015;25(5):763-8.
12. Tai CM, Huang CK, Lee YC, Chang CY, Lee CT, Lin JT. Increase in gastroesophageal reflux disease symptoms and erosive esophagitis 1 year after laparoscopic sleeve gastrectomy among obese adults. *Surg Endosc*. 2013;27(4):1260-6.
13. Howard DD, Caban AM, Cendan JC, Ben-David K. Gastroesophageal reflux after sleeve gastrectomy in morbidly obese patients. *Surg Obes Relat Dis*. 2011;7(6):709-13.
14. Matar R, Maselli D, Vargas E, Veeravich J, Bazerbach F, Beran A, et al. Esophagitis After Bariatric Surgery: Large Cross-sectional Assessment of an Endoscopic Database. *Obes Surg*. 2020;30(1):161-8.
15. Gu L, Chen B, Du N, Fu R, Huang X, Mao F, et al. Relationship Between Bariatric Surgery and Gastroesophageal Reflux Disease: a Systematic Review and Meta-analysis. *Obes Surg*. 2019;29(12):4105-13.
16. DuPree CE, Blair K, Steele SR, Martin MJ. Laparoscopic sleeve gastrectomy in patients with preexisting gastroesophageal reflux disease : a national analysis. *JAMA Surg*. 2014;149(4):328-34.
17. Carter PR, LeBlanc KA, Hausmann MG, Kleinpeter KP, deBarros SN, Jones SM. Association between gastroesophageal reflux disease and laparoscopic sleeve gastrectomy. *Surg Obes Relat Dis*. 2011;7(5):569-72.

18. Borbély Y, Schaffner E, Zimmermann L, Huguenin M, Plitzko G, Nett P, Kröll D. De novo gastroesophageal reflux disease after sleeve gastrectomy: role of preoperative silent reflux. *Surg Endosc.* 2019;33(3):789-93.
19. Raj PP, Bhattacharya S, Misra S, Kumar SS, Khan MJ, Gunasekaran SC, Palanivelu C. Gastroesophageal reflux and related physiologic changes after sleeve gastrectomy and Roux-en-Y gastric bypass: a prospective comparative study. *Surgery for Obesity and Related Diseases.* 2019;15(8):1261-9.
20. Salminen P, Grönroos S, Helmiö M, Hurme S, Juuti A, Juusela R, et al. Effect of Laparoscopic Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass on Weight Loss, Comorbidities, and Reflux at 10 Years in Adult Patients With Obesity: The SLEEVEPASS Randomized Clinical Trial. *JAMA Surg.* 2022;157(8):656-66.
21. Juodeikis Ž, Brimas G. Long-term results after sleeve gastrectomy: A systematic review. *Surg Obes Relat Dis.* 2017;13(4):693-9.
22. Mion F, Tolone S, Garros A, Savarino E, Pelascini E, Robert M, et al. High-resolution Impedance Manometry after Sleeve Gastrectomy: Increased Intra-gastric Pressure and Reflux are Frequent Events. *Obes Surg.* 2016;26(10):2449-56.
23. Peterli R, Wölnerhanssen BK, Peters T, Vetter D, Kröll D, Borbély Y, et al. Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients With Morbid Obesity: The SM-BOSS Randomized Clinical Trial. *Jama.* 2018;319(3):255-65.
24. Genco A, Soricelli E, Casella G, Maselli R, Castagneto-Gissey L, Di Lorenzo N, Basso N. Gastroesophageal reflux disease and Barrett's esophagus after laparoscopic sleeve gastrectomy: a possible, underestimated long-term complication. *Surgery for Obesity and Related Diseases.* 2017;13(4):568-74.
25. Han Y, Jia Y, Wang H, Cao L, Zhao Y. Comparative analysis of weight loss and resolution of comorbidities between laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass: A systematic review and meta-analysis based on 18 studies. *International Journal of Surgery.* 2020;76:101-10.
26. Oor JE, Roks DJ, Ünlü Ç, Hazebroek EJ. Laparoscopic sleeve gastrectomy and gastroesophageal reflux disease: a systematic review and meta-analysis. *Am J Surg.* 2016;211(1):250-67.
27. Yeung KTD, Penney N, Ashrafian L, Darzi A, Ashrafian H. Does Sleeve Gastrectomy Expose the Distal Esophagus to Severe Reflux?: A Systematic Review and Meta-analysis. *Ann Surg.* 2020;271(2):257-65.
28. Znamirovski P, Kołomańska M, Mazurkiewicz R, Tymchyshyn O, Nawacki Ł. GERD as a Complication of Laparoscopic Sleeve Gastrectomy for the Treatment of Obesity: A Systematic Review and Meta-Analysis. *J Pers Med.* 2023;13(8).
29. Melissas J, Koukouraki S, Askoxylakis J, Stathaki M, Daskalakis M, Perisinakis K, Karkavitsas N. Sleeve gastrectomy: a restrictive procedure? *Obes Surg.* 2007;17(1):57-62.
30. Melissas J, Daskalakis M, Koukouraki S, Askoxylakis I, Metaxari M, Dimitriadis E, et al. Sleeve gastrectomy-a "food limiting" operation. *Obes Surg.* 2008;18(10):1251-6.
31. Felinska E, Billeter A, Nickel F, Contin P, Berth F, Chand B, et al. Do we understand the pathophysiology of GERD after sleeve gastrectomy? *Annals of the New York Academy of Sciences.* 2020;1482(1):26-35.
32. Che F, Nguyen B, Cohen A, Nguyen NT. Prevalence of hiatal hernia in the morbidly obese. *Surg Obes Relat Dis.* 2013;9(6):920-4.
33. Clapp B, Liggett E, Barrientes A, Aguirre K, Marwaha V, Tyroch A. Concomitant Hiatal Hernia Repair with Sleeve Gastrectomy: A 5-Year Analysis. *Jsls.* 2020;24(4).
34. Greenan G, Rogers BD, Gyawali CP. Proximal Gastric Pressurization After Sleeve Gastrectomy Associates With Gastroesophageal Reflux. *Am J Gastroenterol.* 2023;118(12):2148-56.
35. Keidar A, Appelbaum L, Schweiger C, Elazary R, Baltasar A. Dilated upper sleeve can be associated with severe postoperative gastroesophageal dysmotility and reflux. *Obes Surg.* 2010;20(2):140-7.
36. Spivak H, Rubin M, Sadot E, Pollak E, Feygin A, Goitein D. Laparoscopic sleeve gastrectomy using 42-French versus 32-French bougie: the first-year outcome. *Obes Surg.* 2014;24(7):1090-3.
37. Chang PC, Chen KH, Jhou HJ, Chen PH, Huang CK, Lee CH, Chang TW. Promising effects of 33 to 36 Fr. bougie calibration for laparoscopic sleeve gastrectomy: a systematic review and network meta-analysis. *Sci Rep.* 2021;11(1):15217.
38. Wang Y, Yi XY, Gong LL, Li QF, Zhang J, Wang ZH. The effectiveness and safety of laparoscopic sleeve gastrectomy with different sizes of bougie calibration: A systematic review and meta-analysis. *Int J Surg.* 2018;49:32-8.
39. Zarzycki P, Rymarowicz J, Małczak P, Pisarska-Adamczyk M, Mulek R, Binda A, et al. Differences in Technical Aspects of Primary Sleeve Gastrectomy Prior to Redo Bariatric Surgery-A Multicenter Cohort Study (PROSS Study). *Medicina (Kaunas).* 2023;59(4).

40. Dhanabalsamy N, Rammohan R, Quirante FP, Montorfano L, Menzo EL, Szomstein S, Rosenthal R. Laparoscopic Sleeve Gastrectomy: Does Bougie Size Affect Weight Loss? *Surgery for Obesity and Related Diseases*. 2016;12(7):S145.
41. Garay M, Balagué C, Rodríguez-Otero C, Gonzalo B, Domenech A, Pernas JC, et al. Influence of antrum size on gastric emptying and weight-loss outcomes after laparoscopic sleeve gastrectomy (preliminary analysis of a randomized trial). *Surg Endosc*. 2018;32(6):2739-45.
42. Masood M, Low D, Deal SB, Kozarek RA. Gastroesophageal Reflux Disease in Obesity: Bariatric Surgery as Both the Cause and the Cure in the Morbidly Obese Population. *J Clin Med*. 2023;12(17).
43. Laine L, DeVault K, Katz P, Mitev S, Lowe J, Hunt B, Spechler S. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial. *Gastroenterology*. 2023;164(1):61-71.
44. Shinozaki S, Osawa H, Hayashi Y, Miura Y, Lefor AK, Yamamoto H. Long-term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor-resistant gastroesophageal reflux disease. *Biomed Rep*. 2021;14(3):32.
45. Niikura R, Yamada A, Hirata Y, Hayakawa Y, Takahashi A, Shinozaki T, et al. Efficacy of Vonoprazan for Gastroesophageal Reflux Symptoms in Patients with Proton Pump Inhibitor-resistant Non-erosive Reflux Disease. *Intern Med*. 2018;57(17):2443-50.
46. Mazer L, Yu JX, Bhalla S, Platt K, Watts L, Volk S, Schulman AR. Pneumatic Balloon Dilation of Gastric Sleeve Stenosis Is Not Associated with Weight Regain. *Obes Surg*. 2022;32(7):1-6.
47. Dhorepatil AS, Cottam D, Surve A, Medlin W, Zaveri H, Richards C, Cottam A. Is pneumatic balloon dilation safe and effective primary modality of treatment for post-sleeve gastrectomy strictures? A retrospective study. *BMC Surg*. 2018;18(1):52.
48. Chang SH, Popov VB, Thompson CC. Endoscopic balloon dilation for treatment of sleeve gastrectomy stenosis: a systematic review and meta-analysis. *Gastrointest Endosc*. 2020;91(5):989-1002.e4.
49. Kurien R, Menon S. Balloon dilation in sleeve gastrectomy stenosis: a simple solution to an occasionally tricky problem. *Gastrointestinal Endoscopy*. 2020;91(5):1003-4.
50. Joo MK. Endoscopic Approach for Major Complications of Bariatric Surgery. *Clin Endosc*. 2017;50(1):31-41.
51. Gagner M, Kemmeter P. Comparison of laparoscopic sleeve gastrectomy leak rates in five staple-line reinforcement options: a systematic review. *Surg Endosc*. 2020;34(1):396-407.
52. Burgos AM, Braghetto I, Csendes A, Maluenda F, Korn O, Yarmuch J, Gutierrez L. Gastric leak after laparoscopic-sleeve gastrectomy for obesity. *Obes Surg*. 2009;19(12):1672-7.
53. Bekheit M, Katri KM, Nabil W, Sharaan MA, El Kayal ESA. Earliest signs and management of leakage after bariatric surgeries: Single institute experience. *Alexandria Journal of Medicine*. 2013;49(1):29-33.
54. Abou Rached A, Basile M, El Masri H. Gastric leaks post sleeve gastrectomy: review of its prevention and management. *World J Gastroenterol*. 2014;20(38):13904-10.
55. Csendes A, Díaz JC, Burdiles P, Braghetto I, Maluenda F, Nava O, Korn O. Classification and treatment of anastomotic leakage after extended total gastrectomy in gastric carcinoma. *Hepatogastroenterology*. 1990;37 Suppl 2:174-7.
56. Welsch T, von Frankenberg M, Schmidt J, Büchler MW. [Diagnosis and definition of anastomotic leakage from the surgeon's perspective]. *Chirurg*. 2011;82(1):48-55.
57. Larsen M, Kozarek R. Therapeutic endoscopy for the treatment of post-bariatric surgery complications. *World J Gastroenterol*. 2022;28(2):199-215.
58. Wikiel KJ, McConnell B, Bollinger D, Abbitt D, Ahrendt SA, McCarter MD, et al. Endoluminal wound vacuum therapy for gastrointestinal leaks: current state and future directions. *Annals of Laparoscopic and Endoscopic Surgery*. 2023;8.
59. Markus A, Henrik BJ, Benedikt R, Alexander H, Thomas B, Clemens S, Jan-Hendrik E. Endoscopic vacuum therapy in salvage and standalone treatment of gastric leaks after bariatric surgery. *Langenbecks Arch Surg*. 2022;407(3):1039-46.
60. Archid R, Wichmann D, Klingert W, Nadiradze G, Hönes F, Archid N, et al. Endoscopic Vacuum Therapy for Staple Line Leaks after Sleeve Gastrectomy. *Obes Surg*. 2020;30(4):1310-5.
61. Kollmann L, Reimer S, Lock JF, Flemming I, Widder A, May J, et al. Endoscopic vacuum therapy as a first-line treatment option for gastric leaks after bariatric surgery: evidence from 10 years of experience. *Surgery for Obesity and Related Diseases*. 2023;19(9):1041-8.

62. Gagner M, Hutchinson C, Rosenthal R. Fifth International Consensus Conference: current status of sleeve gastrectomy. *Surg Obes Relat Dis*. 2016;12(4):750-6.
63. Slater BJ, Collings A, Dirks R, Gould JC, Qureshi AP, Juza R, et al. Multi-society consensus conference and guideline on the treatment of gastroesophageal reflux disease (GERD). *Surg Endosc*. 2023;37(2):781-806.
64. Perez AR, Moncure AC, Rattner DW. Obesity adversely affects the outcome of antireflux operations. *Surg Endosc*. 2001;15(9):986-9.
65. Morgenthal CB, Lin E, Shane MD, Hunter JG, Smith CD. Who will fail laparoscopic Nissen fundoplication? Preoperative prediction of long-term outcomes. *Surg Endosc*. 2007;21(11):1978-84.
66. Kellogg TA, Andrade R, Maddaus M, Slusarek B, Buchwald H, Ikramuddin S. Anatomic findings and outcomes after antireflux procedures in morbidly obese patients undergoing laparoscopic conversion to Roux-en-Y gastric bypass. *Surg Obes Relat Dis*. 2007;3(1):52-7; discussion 8-9.
67. Prachand VN, Alverdy JC. Gastroesophageal reflux disease and severe obesity: Fundoplication or bariatric surgery? *World J Gastroenterol*. 2010;16(30):3757-61.
68. MacVicar S, Mocanu V, Jogiati U, Verhoeff K, Dang J, Birch D, et al. Revisional bariatric surgery for gastroesophageal reflux disease: characterizing patient and procedural factors and 30-day outcomes for a retrospective cohort of 4412 patients. *Surg Endosc*. 2024;38(1):75-84.
69. Langer FB, Bohdjalian A, Shakeri-Leidenmühler S, Schoppmann SF, Zacherl J, Prager G. Conversion from sleeve gastrectomy to Roux-en-Y gastric bypass--indications and outcome. *Obes Surg*. 2010;20(7):835-40.
70. Gautier T, Sarcher T, Contival N, Le Roux Y, Alves A. Indications and mid-term results of conversion from sleeve gastrectomy to Roux-en-Y gastric bypass. *Obes Surg*. 2013;23(2):212-5.
71. Parmar CD, Mahawar KK, Boyle M, Schroeder N, Balupuri S, Small PK. Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass is Effective for Gastro-Oesophageal Reflux Disease but not for Further Weight Loss. *Obes Surg*. 2017;27(7):1651-8.
72. Hendricks L, Alvarenga E, Dhanabalsamy N, Lo Menzo E, Szomstein S, Rosenthal R. Impact of sleeve gastrectomy on gastroesophageal reflux disease in a morbidly obese population undergoing bariatric surgery. *Surg Obes Relat Dis*. 2016;12(3):511-7.
73. Strauss AL, Triggs JR, Tewksbury CM, Soriano I, Wernsing DS, Dumon KR, et al. Conversion to Roux-En-Y Gastric Bypass: a successful means of mitigating reflux after laparoscopic sleeve gastrectomy. *Surg Endosc*. 2023;37(7):5374-9.
74. Salminen P, Helmiö M, Ovaska J, Juuti A, Leivonen M, Peromaa-Haavisto P, et al. Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity: The SLEEVEPASS Randomized Clinical Trial. *JAMA*. 2018;319(3):241-54.
75. Felsenreich DM, Steinlechner K, Langer FB, Vock N, Eichelster J, Bichler C, et al. Outcome of Sleeve Gastrectomy Converted to Roux-en-Y Gastric Bypass and One-Anastomosis Gastric Bypass. *Obes Surg*. 2022;32(3):643-51.
76. Dang JT, Vaughan T, Mocanu V, Mubashir H, Barajas-Gamboa JS, Codina RC, et al. Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass: Indications, Prevalence, and Safety. *Obes Surg*. 2023;33(5):1486-93.
77. Abdemur A, Han SM, Lo Menzo E, Szomstein S, Rosenthal R. Reasons and outcomes of conversion of laparoscopic sleeve gastrectomy to Roux-en-Y gastric bypass for nonresponders. *Surg Obes Relat Dis*. 2016;12(1):113-8.
78. Peng BQ, Zhang GX, Chen G, Cheng Z, Hu JK, Du X. Gastroesophageal reflux disease complicating laparoscopic sleeve gastrectomy: current knowledge and surgical therapies. *Surg Obes Relat Dis*. 2020;16(8):1145-55.
79. Castagneto-Gissey L, Russo MF, D'Andrea V, Genco A, Casella G. Efficacy of Sleeve Gastrectomy with Concomitant Hiatal Hernia Repair versus Sleeve-Fundoplication on Gastroesophageal Reflux Disease Resolution: Systematic Review and Meta-Analysis. *J Clin Med*. 2023;12(9).
80. Carandina S, Zulian V, Nedelcu A, Danan M, Vilallonga R, Nocca D, Nedelcu M. Is It Safe to Combine a Fundoplication to Sleeve Gastrectomy? Review of Literature. *Medicina (Kaunas)*. 2021;57(4).
81. Amor IB, Casanova V, Vanbiervliet G, Bereder JM, Habitan R, Kassir R, Gugenheim J. The Nissen-Sleeve (N-Sleeve): Results of a Cohort Study. *Obes Surg*. 2020;30(9):3267-72.
82. Moon RC, Teixeira AF, Jawad MA. Safety and effectiveness of anterior fundoplication sleeve gastrectomy in patients with severe reflux. *Surg Obes Relat Dis*. 2017;13(4):547-52.

83. Lasnibat JP, Braghetto I, Gutierrez L, Sanchez F. SLEEVE GASTRECTOMY AND FUNDOPLICATION AS A SINGLE PROCEDURE IN PATIENTS WITH OBESITY AND GASTROESOPHAGEAL REFLUX. *Arq Bras Cir Dig.* 2017;30(3):216-21.
84. Le Page PA, Martin D. Laparoscopic partial sleeve gastrectomy with fundoplication for gastroesophageal reflux and delayed gastric emptying. *World J Surg.* 2015;39(6):1460-4.
85. Olmi S, Cesana G, Gambioli A, Bonaldi M, Ferrari D, Uccelli M, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic sleeve + Rossetti fundoplication on weight loss and de novo GERD in patients affected by morbid obesity: a randomized clinical study. *Obes Surg.* 2022;32(5):1451-8.
86. Olmi S, Uccelli M, Cesana GC, Ciccarese F, Oldani A, Giorgi R, et al. Modified laparoscopic sleeve gastrectomy with Rossetti antireflux fundoplication: results after 220 procedures with 24-month follow-up. *Surg Obes Relat Dis.* 2020;16(9):1202-11.
87. Olmi S, Cesana G, D'Angiolella L, Bonaldi M, Uccelli M, Mantovani L. Sleeve gastrectomy with tailored 360° fundoplication according to Rossetti in patients affected by obesity and gastroesophageal reflux: a prospective observational study. *Surg Obes Relat Dis.* 2021;17(6):1057-65.
88. da Silva LE, Alves MM, El-Ajouz TK, Ribeiro PC, Cruz RJ, Jr. Laparoscopic Sleeve-Collis-Nissen Gastropasty: a Safe Alternative for Morbidly Obese Patients with Gastroesophageal Reflux Disease. *Obes Surg.* 2015;25(7):1217-22.
89. Del Genio G, Tolone S, Gambardella C, Bruscianno L, Volpe ML, Gualtieri G, et al. Sleeve Gastrectomy and Anterior Fundoplication (D-SLEEVE) Prevents Gastroesophageal Reflux in Symptomatic GERD. *Obes Surg.* 2020;30(5):1642-52.
90. Di Capua F, Cesana GC, Uccelli M, De Carli SM, Giorgi R, Ferrari D, Olmi S. Sleeve Gastrectomy with Rossetti Fundoplication Increases Lower Esophageal Sphincter Tone Preventing Gastroesophageal Reflux Disease: High-Resolution Manometry Assessment. *J Laparoendosc Adv Surg Tech A.* 2023;33(1):44-51.
91. Uccelli M, Cesana GC, Ciccarese F, Oldani A, Giorgi R, De Carli SM, et al. Laparoscopic sleeve gastrectomy with Rossetti fundoplication: long-term (5-year) follow-up. *Surg Obes Relat Dis.* 2022;18(10):1199-205.
92. Nocca D, Skalli EM, Boulay E, Nedelcu M, Michel Fabre J, Loureiro M. Nissen Sleeve (N-Sleeve) operation: preliminary results of a pilot study. *Surg Obes Relat Dis.* 2016;12(10):1832-7.
93. Riva CG, Asti E, Lazzari V, Aquilino K, Siboni S, Bonavina L. Magnetic Sphincter Augmentation After Gastric Surgery. *Jsls.* 2019;23(4).
94. Hawasli A, Sadoun M, Meguid A, Dean M, Sahly M, Hawasli B. Laparoscopic placement of the LINX® system in management of severe reflux after sleeve gastrectomy. *Am J Surg.* 2019;217(3):496-9.
95. Desart K, Rossidis G, Michel M, Lux T, Ben-David K. Gastroesophageal Reflux Management with the LINX® System for Gastroesophageal Reflux Disease Following Laparoscopic Sleeve Gastrectomy. *J Gastrointest Surg.* 2015;19(10):1782-6.
96. Broderick RC, Smith CD, Cheverie JN, Omelanczuk P, Lee AM, Dominguez-Profeta R, et al. Magnetic sphincter augmentation: a viable rescue therapy for symptomatic reflux following bariatric surgery. *Surg Endosc.* 2020;34(7):3211-5.
97. Khaitan L, Hill M, Michel M, Chiasson P, Woodworth P, Bell R, et al. Feasibility and Efficacy of Magnetic Sphincter Augmentation for the Management of Gastroesophageal Reflux Disease Post-Sleeve Gastrectomy for Obesity. *Obes Surg.* 2023;33(1):387-96.
98. Rausa E, Manfredi R, Kelly ME, Bianco F, Aiolfi A, Bonitta G, et al. Magnetic Sphincter Augmentation Placement for Recalcitrant Gastroesophageal Reflux Disease Following Bariatric Procedures: A Systematic Review and Bayesian Meta-Analysis. *J Laparoendosc Adv Surg Tech A.* 2021;31(9):1034-9.
99. Novikov AA, Afaneh C, Saumoy M, Parra V, Shukla A, Dakin GF, et al. Endoscopic Sleeve Gastropasty, Laparoscopic Sleeve Gastrectomy, and Laparoscopic Band for Weight Loss: How Do They Compare? *J Gastrointest Surg.* 2018;22(2):267-73.
100. Sharaiha RZ, Kedia P, Kumta N, Aronne LJ, Kahaleh M. Endoscopic sleeve plication for revision of sleeve gastrectomy. *Gastrointest Endosc.* 2015;81(4):1004.
101. Maselli DB, Alqahtani AR, Abu Dayyeh BK, Elahmedi M, Storm AC, Matar R, et al. Revisional endoscopic sleeve gastropasty of laparoscopic sleeve gastrectomy: an international, multicenter study. *Gastrointest Endosc.* 2021;93(1):122-30.
102. Nduma BN, Mofor KA, Tatang JT, Ekhatior C, Ambe S, Fonkem E. Endoscopic Gastric Sleeve: A Review of Literature. *Cureus.* 2023;15(3):e36353.

103. Fayad L, Adam A, Schweitzer M, Cheskin LJ, Ajayi T, Dunlap M, et al. Endoscopic sleeve gastropasty versus laparoscopic sleeve gastrectomy: a case-matched study. *Gastrointest Endosc.* 2019;89(4):782-8.
104. Brethauer SA, Chand B, Schauer PR, Thompson CC. Transoral gastric volume reduction as intervention for weight management: 12-month follow-up of TRIM trial. *Surg Obes Relat Dis.* 2012;8(3):296-303.
105. Qumseya BJ, Qumsiyeh Y, Ponniah SA, Estores D, Yang D, Johnson-Mann CN, et al. Barrett's esophagus after sleeve gastrectomy: a systematic review and meta-analysis. *Gastrointest Endosc.* 2021;93(2):343-52.e2.
106. Campos GM, Mazzini GS, Altieri MS, Docimo S, Jr., DeMaria EJ, Rogers AM. ASMBS position statement on the rationale for performance of upper gastrointestinal endoscopy before and after metabolic and bariatric surgery. *Surg Obes Relat Dis.* 2021;17(5):837-47.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.